drugset / Trial / NCT04469062
A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate if study drug mirikizumab is safe and effective compared to vedolizumab and placebo in participants with moderately to severely active ulcerative colitis (UC).
Timeline
- Start
- 2021-04-20
- Primary completion
- 2024-03-13
- Completion
- 2024-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | — | Intravenous |
| Comparator | Vedolizumab | Monoclonal antibody | — | Intravenous |